Pharmabiz17h
Govt should roll out comprehensive National Cancer Care Policy with dedicated funding outlay: FICCI-EY Parthenon Report
Govt should roll out comprehensive National Cancer Care Policy with dedicated funding outlay: FICCI-EY Parthenon Report: Our ...
Pharmabiz23h
Oversimplification about integration of traditional & modern treatment systems creates confusion: Dr Kotecha
Oversimplification about integration of traditional & modern treatment systems creates confusion: Dr Kotecha: Peethaambaran ...
Pharmabiz13h
Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis
Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis: Oslo, Norway Tuesday, November 12, 2024, 18:00 Hrs ...
Pharmabiz17h
GE HealthCare, RadNet collaborate to transform imaging systems and accelerate the adoption of AI with SmartTechnology
Chicago, Illinois Tuesday, November 12, 2024, 14:00 Hrs [IST] ...
Pharmabiz21h
Relief Therapeutics announces positive final results of RLF-TD011 trial in epidermolysis bullosa
Relief Therapeutics announces positive final results of RLF-TD011 trial in epidermolysis bullosa: Geneva Tuesday, November 12, 2024, 10:00 Hrs [IST] Relief Therapeutics Holding SA ...
Pharmabiz16h
EnteroBiotix reports positive results from phase 1b IMPuLCE study of EBX-102 in liver cirrhosis
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced positive results from its phase 1b IMPuLCE study ...
Pharmabiz10h
ViiV Healthcare deepens its commitment to under-served LGBTI communities, pledging $7.8million in new funding
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced it is pledging $7.8 million to the ‘Fund our Futures’ campaign led by ...
Pharmabiz18h
Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024
Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...
Pharmabiz9h
STEERLife & Callidus Research Laboratories forge strategic partnership to accelerate innovative drug development
STEERLife, a pioneer in pharmaceutical development technologies, and Callidus Research Laboratories, a formulation development services company with a wealth of experience in comprehensive ...
Pharmabiz19h
Healthium and HSSC ink MoU to enhance certification in skill development for Indian healthcare
Healthium and HSSC ink MoU to enhance certification in skill development for Indian healthcare: Our Bureau, Bengaluru Tuesday, November 12, 2024, 12:15 Hrs [IST] Healthium Medtech ...
Pharmabiz10h
Neurizon Therapeutics receives positive opinion on orphan medicinal product designation for NUZ-001 in Europe
Neurizon Therapeutics Limited (Neurizon), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced it has received notice of a positive opinion from the European ...
Pharmabiz20h
GenScript Biotech establishes new operations and logistics hub in Sydney, Australia
GenScript Biotech establishes new operations and logistics hub in Sydney, Australia: New Jersey, USA Tuesday, November 12, 2024, 11:00 Hrs [IST] GenScript Biotech Corporation (Gen ...